Fresh analysis suggests that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Research printed in a leading health publication demonstrates that while overweight individuals can lose substantial amounts of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"People using such treatments must be aware of the potential of quick weight regain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment weight within about 18 months.
Weighing Treatments
The analysis, which looked at dozens of studies involving thousands of patients, compared the results of these new drugs with older methods.
Researchers note that people who shed pounds through dieting usually experience a less rapid weight regain—around 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Experts believe the mode of action of the jabs accounts for the accelerated regain.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than normal may cause the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement means appetite is unsuppressed, making overeating a significant risk."
A Lifelong Disease?
The NHS advise the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals contend that, considering the significant potential of relapse, the treatment is often ongoing.
This opinion is echoed by pharmaceutical companies, who note that the findings "emphasize the persistent character of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
Users who have stopped the jabs explain a powerful resurgence of hunger.
"I experienced a trigger that goes on and I was suddenly extremely hungry," recalled one woman.
The struggle is exacerbated if patients have not adopted lasting lifestyle or habit changes during therapy.
Widespread Interest
Recent estimates indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is greater among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a standalone cure and long-term success likely depends on ongoing lifestyle support.
